IMMPNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRRUF
IMMUTEP Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Oct 24, 2025
$3.17−0.03 (-0.94%)
Close on Oct 19, 2026
Immutep statistics
Financials through Jun 30, 2025, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Immutep | Industry median |
|---|---|---|
| Market Cap | A$663.34M | A$18.21M |
| Enterprise Value | A$595.93M | A$10.48M |
| PS Ratio | 64.21 | |
| PB Ratio | 4.62 | |
| P/TBV Ratio | 4.62 |
Enterprise value
| Measure | Immutep | Industry median |
|---|---|---|
| EV / Sales | 57.68 |
Income (trailing twelve months)
| Measure | Immutep | Industry median |
|---|---|---|
| Revenue | A$10.33M | |
| Pretax Income | -A$61.43M | -A$12.08M |
| Net Income | -A$61.43M | |
| EBITDA | -A$59.01M | |
| EPS (Diluted) | -0.04 AUD | -0.19 AUD |
Margins
| Measure | Immutep | Industry median |
|---|---|---|
| Pretax Margin | -594.6% | |
| Profit Margin | -594.6% | |
| EBITDA Margin | -571.1% | |
| FCF Margin | -601.0% |
Returns
| Measure | Immutep | Industry median |
|---|---|---|
| Return on Equity (ROE) | -42.8% | |
| Return on Assets (ROA) | -39.1% |
Growth
| Measure | Immutep | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 31.8% | |
| Revenue Growth (3Y CAGR) | 15.2% | |
| Revenue Growth (5Y CAGR) | -8.94% |
Balance sheet
| Measure | Immutep | Industry median |
|---|---|---|
| Cash & Short-Term Investments | A$67.41M | A$33.16M |
| Net Cash (Debt) | A$67.41M | A$33.16M |
| Net Cash Per Share | 0.05 AUD | 0.05 AUD |
| Equity (Book Value) | A$143.64M | |
| Book Value Per Share | 0.10 AUD | |
| Tangible Book Value | A$143.64M | |
| Working Capital | A$136.34M | A$42.34M |
Financial position
| Measure | Immutep | Industry median |
|---|---|---|
| Current Ratio | 11.69 | 5.09 |
| Quick Ratio | 6.06 | 2.86 |
Cash flow (trailing twelve months)
| Measure | Immutep | Industry median |
|---|---|---|
| Operating Cash Flow | -A$62.05M | -A$11.45M |
| Capital Expenditures | -A$45.77K | |
| Free Cash Flow | -A$62.10M | |
| FCF Per Share | -0.04 AUD |
Efficiency
| Measure | Immutep | Industry median |
|---|---|---|
| Asset Turnover | 0.07 | |
| Revenue Per Employee | A$202.58K | |
| Profits Per Employee | -A$1.20M | |
| Employee Count | 51 |
Dividends and yields
| Measure | Immutep | Industry median |
|---|---|---|
| Earnings Yield | -9.26% | |
| FCF Yield | -9.36% |
Shares
| Measure | Immutep | Industry median |
|---|---|---|
| Shares Outstanding | 1,460,390,000 | 322,848,000 |
| Shares Change (YoY) | 21.2% | 21.2% |
| Float | 1,447,210,000 | 316,596,000 |
| Shares Held by Insiders | 0.90% | 1.94% |
Taxes
| Measure | Immutep | Industry median |
|---|---|---|
| Income Tax | A$0 |
Scores
| Measure | Immutep | Industry median |
|---|---|---|
| Altman Z-Score | 26.96 | -0.37 |
| Piotroski F-Score | 1 |
Calculated by StockData from Immutep's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.